Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics Corporation filed a current report stating that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company used this report to make investors aware of the new earnings release without having the detailed numbers directly in the filing.
The press release, dated November 4, 2025, is attached as Exhibit 99.1 and is incorporated by reference, but is furnished rather than filed, which limits certain legal liabilities under securities laws. The company also included a cover page interactive data file in Inline XBRL format as Exhibit 104 to support electronic reporting and data analysis.
PROCEPT BioRobotics Corporation updated its form of Change of Control and Severance Agreement for executive officers below the CEO to better align with market data. The revised form increases severance for involuntary terminations not tied to a change of control from six months to twelve months, clarifies that performance-based awards accelerated on a change of control termination will be treated as achieved at no less than target performance, and changes change-of-control cash payments to be made in a single lump sum. The company will ask eligible executives to execute amended agreements consistent with the revised form and has filed the form as Exhibit 10.1.
PROCEPT BioRobotics Corporation updated its form of Change of Control and Severance Agreement for executive officers below the CEO to better align with market data. The revised form increases severance for involuntary terminations not tied to a change of control from six months to twelve months, clarifies that performance-based awards accelerated on a change of control termination will be treated as achieved at no less than target performance, and changes change-of-control cash payments to be made in a single lump sum. The company will ask eligible executives to execute amended agreements consistent with the revised form and has filed the form as Exhibit 10.1.
Larry L. Wood, President, CEO and a director of PROCEPT BioRobotics Corporation (PRCT), reported equity awards dated 09/02/2025. The filing shows an acquisition of 182,392 restricted stock units (RSUs) at $0, increasing his beneficial ownership of common stock to 185,595 shares after adjustment for the forfeiture of 2,765 unvested RSUs. The RSUs vest one-quarter on 09/02/2026 and then monthly at one-twelfth of the remaining quarterly amount thereafter, subject to continued service. The filing also discloses a stock option grant for 319,618 shares with an exercise price of $39.57, exercisable through 09/01/2036, vesting one-quarter on 09/02/2026 and then monthly thereafter. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.
Insider purchase reported: The Form 4 shows that Frederic Moll, a director of PROCEPT BioRobotics Corp (PRCT), bought 20,000 shares on 08/13/2025 at a weighted average price of $39.2569 per share. After the transactions, he beneficially owns 863,159 shares. The filing notes the shares were acquired in multiple trades with prices ranging from $38.71 to $39.645 and offers to provide a break‑down on request. The form was signed by an attorney‑in‑fact on 08/14/2025.
Nouri Alaleh, EVP and Chief Legal Officer of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 11,000 shares on 08/14/2025. The exercise was a cash exercise at an exercise price of $4.52 per share for options that are fully vested and exercisable. After the transaction the reporting person beneficially owns 72,473 shares of common stock directly and holds derivative interests corresponding to 11,000 underlying shares, with 54,452 derivative securities beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.